Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 26;10(4):e2020094.
doi: 10.5826/dpc.1004a94. eCollection 2020 Oct.

An Open-Label Prospective Study to Compare the Efficacy and Safety of Topical Fluticasone Versus Tacrolimus in the Proactive Treatment of Atopic Dermatitis

Vinodhini R Mudaliyar  1 , Asha Pathak  1 , Alok Dixit  1 , Sweta S Kumar  2
Affiliations

An Open-Label Prospective Study to Compare the Efficacy and Safety of Topical Fluticasone Versus Tacrolimus in the Proactive Treatment of Atopic Dermatitis

Vinodhini R Mudaliyar et al. Dermatol Pract Concept. .

Abstract

Background: Atopic dermatitis (AD), a chronic, recurrent inflammatory skin condition primarily affects children. Topical treatment, systemic treatment, and phototherapy are mainstays of treatment. Topical corticosteroids (TCS) are first-line therapy for AD but are associated with various adverse effects. Topical calcineurin inhibitors (TCI) can be used as an alternative to TCS.

Objective: The aim of the study is to compare the efficacy of topical preparations of fluticasone and tacrolimus in reducing the severity of disease and, to assess the quality of life (QoL), and to estimate if any association exists between severity of disease and QoL.

Methods: Thirty-seven children with AD randomly received one of the 2 topical treatments, with daily application for the first 4 weeks in the acute phase and twice weekly for next 4 weeks in the maintenance phase. The severity of disease was assessed using SCORing Atopic Dermatitis (SCORAD), and QoL was assessed using the Children's Dermatology Life Quality Index (CDLQI).

Results: At the end of the acute phase, there was a reduction in SCORAD score of 69.29% in the fluticasone group and 64.2% in the tacrolimus group (P < 0.001). In the maintenance phase, the score had risen in the fluticasone group by a mean difference of 0.81, while in the tacrolimus group it decreased by 0.99. Both fluticasone and tacrolimus groups improved in children's QoL (P < 0.001). Positive correlation (r = 0.4668) exists between SCORAD and QoL. The most common adverse skin reaction noted was skin burning with tacrolimus.

Conclusions: Fluticasone and tacrolimus are equally efficacious in the treatment of AD and have similar benefits with children's QoL. Tacrolimus is better than fluticasone at reducing the extent of lesions.

Keywords: atopic dermatitis; fluticasone propionate; tacrolimus; topical calcineurin inhibitors; topical corticosteroids.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Changes in SCORAD in both treatment groups at week 0 (baseline), 2, 4 (end of acute phase), 6, and 8 (end of maintenance phase) [Mean ± SEM]. SCORAD = scoring atopic dermatitis.
Figure 2
Figure 2
Changes in CDLQI in both treatment groups at week 0 (baseline), 2, 4 (end of acute phase), 6, and 8 (end of maintenance phase) [Mean ± SEM]. CDLQI = children’s dermatology life quality index.
Figure 3
Figure 3
Changes in the extent of lesions (BSA) in both treatment groups at week 0 (baseline), 2, 4 (end of acute phase), 6, and 8 (end of maintenance phase) [Mean ± SEM]. BSA = body surface area.
Figure 4
Figure 4
Changes in the subjective symptoms in both treatment groups at week 0 (baseline), 2, 4 (end of acute phase), 6, and 8 (end of maintenance phase) [Mean ± SEM].
Figure 5
Figure 5
Association between SCoring atopic dermatitis (SCORAD) and children’s dermatology life quality index (CDLQI).
See this image and copyright information in PMC

References

    1. Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic dermatitis in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 1999;103(1 pt 1):125–138. doi: 10.1016/S0091-6749(99)70536-1. - DOI - PubMed
    1. Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis Child. 1997;76(2):159–162. doi: 10.1136/adc.76.2.159. - DOI - PMC - PubMed
    1. Filanovsky MG, Pootongkam S, Tamburro JE, Smith MC, Ganocy SJ, Nedorost ST. The financial and emotional impact of atopic dermatitis on children and their families. J Pediatr. 2016;169:285–290. doi: 10.1016/j.jpeds.2015.10.077. - DOI - PubMed
    1. Rajagopalan M, De A, Godse K, et al. Guidelines on management of atopic dermatitis in India: an evidence-based review and an expert consensus. Indian J Dermatol. 2019;64(3):166–181. doi: 10.4103/ijd.IJD_683_18. - DOI - PMC - PubMed
    1. Ahluwalia A. Topical glucocorticoids and the skin—mechanisms of action: an update. Mediators Inflamm. 1998;7(3):183–193. doi: 10.1080/09629359891126. - DOI - PMC - PubMed

LinkOut - more resources